HIV infection is an independent risk factor for liver steatosis: A study in HIV mono-infected patients compared to uninfected paired controls and associated.

Slides:



Advertisements
Similar presentations
Case Report Ana Carolina Cardoso
Advertisements

Change in Abdominal Obesity & Risk of Coronary Calcification Siamak Sabour, MD, MSc, DSc, PhD, Postdoc Clinical Epidemiologist Persian International Epidemiology.
Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,
Predictors of elevated transaminase levels in patients with central obesity V. Papastergiou, G. Ntetskas, L. Skorda, F. Lambrianou, K. Roufas, E. Asonitis,
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Prevalence of anal Human Papillomavirus (HPV) infection and anal squamous intraepithelial.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
Ambulatory Blood Pressure Profiles in Adolescents with Type 1 Diabetes Andrew J. Ellis 1,2, B.A.; David M. Maahs 2, M.D. Ph.D.; Franziska K. Bishop 2,
Patients in routine HIV clinical care at-risk for potentially transmitting HIV in the “test and treat” era of HIV prevention Crane, HM, Mimiaga, M, Feldman,
Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Washington D.C., USA, July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,
1FHI 360 Nigeria. 2USAID Nigeria
Metabolic Syndrome, Diabetes, and Cognitive Impairment in the Era of Combination Antiretroviral Therapy Allen McCutchan 1, Jennifer Marquie-Beck 1, Scott.
Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.
SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar Dr.PH. Batch 5 1.
1. Relation between dietary macronutrient and fiber intake with metabolic syndrome in Tehranian adults: Tehran Lipid and Glucose Study Hosseinpour S,
Sense of coherence and carotid artery intima media thickness measurements: presenting four case reports from the Spili cohort in rural Crete, Greece D.
The Interplay of the Osteoprotegerin/RANKL Axis and Dysfunctional HDL in HIV-Infected Adults AIDS Clinical Trials Group Study NWCS 332/A5078 Kelesidis.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients Dr. Mya Thandar.
PrEP uptake and associated factors among MSM and TGW in the PrEP Brasil demonstration project Brenda Hoagland, Valdilea G. Veloso, Raquel B. De Boni, José.
#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.
Triglycerides,LDL cholesterol and HOMA score predict the virological response in HIV/HCV co-infected patients treated with Pegylated interferon alpha 2a.
High level of low density lipoprotein cholesterol in adult children of patients with premature coronary heart disease: relation to own and parental characteristics.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar DrPH Batch 5 1.
Metabolic Syndrome in HIV- Infected Patients from MTCT-Plus, Thai Outpatient Population J. JANTARAPAKDE1,2,*, C. CHATURAWIT1,2, S. PENGNONYANG1,2, W. PIMA1,
Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.
Dr. I. Selvaraj Indian Railways Medical Service B.Sc., M.B.B.S., M.D.,D.P.H., D.I.H., PGCHFW ( NIHFW,New Delhi)., Life member of Indian Association of.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.
The short term effects of metabolic syndrome and its components on all-cause-cause mortality-the Taipei Elderly Health Examination Cohort Wen-Liang Liu.
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
MRI Detection of Sub Clinical Structural Cardiac Dysfunction in HIV Positive Men Dr Aisling Loy.
DOES LEPTIN LEVELS AFFECT CARDIOMETABOLIC FACTORS INDEPENDENTLY OF ADIPOSITY IN OBESE BRAZILIAN CHILDREN? Maria Edna Melo 1,2,3, Clarissa TH Fujiwara 1,
METHODS INTRODUCTION I Webster, C Westcott, C Marincowitz, N Mashele, P De Boever, N Goswami, H Strijdom Division of Medical Physiology, Faculty of Medicine.
PREVALENCE AND RISK FACTORS FOR NON- ALCOHOLIC FATTY LIVER DISEASE AMONG AN URBAN AGING ADULT SRI LANKAN POPULATION– RAGAMA HEALTH STUDY 7-YEAR FOLLOW.
SuPAR and sICAM-1 as Immune Markers for Treatment Response in Ethiopian TB patients with and without HIV co-infection Wegene T. Mekasha ICASA, Addis Ababa.
Incidence of Insulin Resistance, the Metabolic Syndrome and Lipodystrophy in a 3 Year Cohort of HIV-Infected Patients Starting Antiretroviral Therapy in.
Matching methods for estimating causal effects Danilo Fusco Rome, October 15, 2012.
Oral Abstract WEAB0101 Trends and predictors of non-communicable disease multi-morbidity among HIV-infected adults initiating ART in Brazil,
Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral.
CERAD immediate memory verbal fluency (animals)
Higher HDL, better brain
National Hepatitis C Database
results of the METAFIB study
GEORGIA TORRES PhD (CSCS)
High level of retention and adherence at week 48 for MSM and TGW enrolled in the PrEP Brasil demonstration study Beatriz Grinsztejn, Brenda Hoagland, Ronaldo.
Non-metabolic syndrome mean (DS) Metabolic syndrome mean (DS)
4th IAS Conference , Sydney, Australia, July 2007
Factors affecting virological failure in patients receiving antiretroviral therapy: a prospective HIV Clinical cohort in rural Uganda. Patrick Kazooba1,
When Military Fitness Standards No Longer Apply
Berket Yemane, Melaku Umeta, Fikre Enquselassie, Wondwossen Amogne
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
Factors Associated with Low Bone Mineral Density (BMD) in a Large Cohort of HIV-Infected U.S. Adults – Baseline Results from the SUN Study # 836 ET Overton1,
Chronic Kidney Disease in HIV Infection: An Urban Epidemic
Associations of Diet and Lifestyle with Hyperlipidemia for the Middle-Aged and Elderly in the Guangxi Bai Ku Yao and Han Populations Yin Ruixing, MD: Guangxi.
Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53
The cost-effectiveness of HIV pre-exposure prophylaxis in high-risk men who have sex with men and transgendered women in Brazil Paula M. Luz, Ben Osher,
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Clinical outcome after SVR: ANRS CO22 HEPATHER
Impact of metabolic risk factors on HCC
Management and Development for Health (MDH)
Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.
The prevalence of Recurrent Stroke and TIA and the related factors
NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:
Comparison of PI vs PI ATV vs ATV/r BMS 089
Validation of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.
Khai Hoan Tram, Jane O’Halloran, Rachel Presti, Jeffrey Atkinson
Presentation transcript:

HIV infection is an independent risk factor for liver steatosis: A study in HIV mono-infected patients compared to uninfected paired controls and associated risk factors Antonio Pacheco, Hugo Perazzo, Sandra Cardoso, Maria-de-Jesus Fonseca, Rosane Griep, Paulo Lotufo, Isabela Bensenor, Jose Mill, Rodrigo Moreira, Ronaldo Moreira, Ruth Friedman, Marilia Santini-Oliveira, Valdilea G Veloso, Dora Chor, Beatriz Grinsztejn Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro University of São Paulo (USP) Federal University of Espírito Santo (UFES) Abstract number: THAB0205 Session title: HIV and the liver July 26h, 2018

Disclosures The authors have nothing to disclosure

Background Evolution of non-alcoholic fatty liver disease Çç l

The burden of liver steatosis in HIV-infected patients Authors Country N Gold standard Prevalence Factors Morse et al CID 2015 USA 62 Liver biopsy 73% - Mohr et al Medicine 2015 Germany 341 Lombardi et al Dig Liver Dis 2016 UK 125 US 55% Male sex, age, HOMA-IR, GGT Liu et al AP&T 2016 China 80 MRI 29% Triglycerides Macias et al HIV Med 2016 Spain 326 CAP 37% Sebastiani et al J Hepatol 2017 Canada 538 36% BMI, triglycerides Lemoine et al AIDS 2017 France 405 Perazzo et al IAS 2017 Brazil 395 35% MS, cumulative use of D-drugs Impact of HIV infection for development of steatosis ?

Aims To evaluate the prevalence and factors associated with liver steatosis in HIV mono-infected patients compared to uninfected subjects paired for confounding factors

Methods Cohort of HIV patients: HIV-ELSA 649 HIV mono-infected patients who have been followed at INI/FIOCRUZ - Rio de Janeiro - Brazil Cohort of non-HIV subjects: ELSA-Brasil study 15,105 individuals included in a longitudinal multricentric Brazilian study (6 centers) Brazilian Longitudinal Study of Adult Health

Methods Clinical evaluation: anthropometric measures, alcohol intake, co-morbidities and co-medication use, history of HIV infection and c-ART treatment (for HIV-infected patients) Blood tests: analyzed in a centralized laboratory Liver steatosis was defined by Fatty Liver Index (FLI) ≥ 60 Serological biomarker for detection of steatosis Parameters: GGT, BMI, waist circumference and triglycerides Diagnostic value - AUROC = 0.84 [0.81-0.87] - FLI ≥ 60 – Sp=87% FLI = (e0.953*ln(triglycerides, mg/dl)+0.139*BMI + 0.718*ln(GGT) + 0.053*ln(WC) - 15.745) x 100 1 + (e0.953*ln(triglycerides, mg/dl)+0.139*BMI + 0.718*ln(GGT) + 0.053*ln(WC) - 15.745) Bedogni BMC Gastroenterology 2006 China Finland Thailand The Netherlands USA Brazil N=3,548 N=572 N=29,797 N=2,652 N=5,869 N=6,571 FLI - AUROCs 0.76 [0.74-0.77] 0.72 [0.66-0.77] 0.827 [0.822-0.831] 0.813 [0.797-0.830] 0.780 [0.740-0.810] 0.762 [0.745-0.779]

Method for matching The variables used for the matching were selected through a genetic algorithm that searched for the best model fit A propensity score was calculated for HIV-infected patients (HIV-ELSA) and non-HIV subjects (ELSA-Brasil study) The variables used for the matching were selected through a genetic algorithm that searched for the best model fit A propensity score were calculated for cases (HIV-infected patients from the INI-ELSA cohort) and controls (uninfected individuals from the ELSA Brasil study) The methodology of the nearest neighbor propensity score with a caliper of 0.05 – selection of cases and controls Standardized mean difference < 0.25 A nearest neighbor propensity score matching with a caliper of 0.05 was used to select cases (HIV-patients) and controls (non-HIV subjects)

Flow-chart of the study

Characteristics of patients   ELSA-Brasil cohort Uninfected subjects (n=15,105) HIV-ELSA cohort HIV-infected subjects (n=649) p value Demographic characteristics Female sex 8211 (54%) 273 (42%) < 0.001 Age, years 51 (45 - 58) 44 (36 - 51) Black/Pardo ethnicity 6591 (44%) 149 (23%) Education level > 8 years of study 13167 (87%) 339 (52%) Metabolic features BMI, Kg/m² 26.5 (23.9 - 29.8) 24.4 (21.9 - 27.5) Waist circumference, cm 87 (78 - 94) 90 (82 - 99) Type-2 diabetes 2762 (18%) 167 (26%) Dyslipidemia 8784 (58%) 235 (37%) Hypertension 5717 (38%) 202 (31%) Metabolic syndrome 6800 (45%) 212 (33%) Biochemistry GGT, IU/L 27 (18 - 42) 52 (36 - 81) Triglycerides, mg/dL 115 (82 - 166) 120 (85 - 185) 0.007 LDL-cholesterol, mg/dL 129 (107 - 152) 106 (87 - 133) HDL-cholesterol, mg/dL 54 (46 - 65) 42 (35 - 51.8) Data expressed as n (%) or median [IQR]

Prevalence of steatosis = 35% Factors associated with liver steatosis in HIV-infected patients (n=649) Prevalence of steatosis = 35%   No steatosis FLI < 60 (n=418) Steatosis FLI >=60 (n=231) p value Female sex 180 (43%) 93 (40%) 0.542 Age, years 42 (34 - 50) 46 (40 - 52) < 0.001 Black/Pardo ethnicity 105 (25%) 44 (19%) 0.096 Education level > 8 years of study 225 (54%) 114 (49%) 0.312 Metabolic features BMI, Kg/m² 22.8 (20.9 - 24.9) 28.4 (25.7 - 31.9) Waist circumference, cm 81 (76 - 87) 97 (92 - 105) Type-2 diabetes 73 (18%) 94 (41%) Dyslipidemia 133 (32%) 102 (46%) < 0.001  Hypertension 97 (23%) 105 (46%) Metabolic syndrome 56 (13%) 156 (68%) Poor clinical management 162 (39%) 123 (54%) HIV history CD4 count, cells 529 (352 - 708) 586 (408 - 830) Undetectable HIV viral load (< 50copies/mm3) 257 (70%) 164 (77%) 0.057 Nadir CD4 count 226 (104 - 317) 194 (85 - 305) 0.142 c-ART 369 (88%) 207 (90%) 0.700 Duration of c-ART, years 3.3 (0.5 - 9.8) 4.8 (1.7 - 11) Current NNRTI treatment 265 (63%) 159 (69%) 0.191 Current PI treatment 208 (50%) 132 (57%) 0.085 Data expressed as n (%) or median [IQR]

Factors indepentently associated with liver steatosis in the multivariate analysis in HIV-infected patients (n=649)   OR (95% CI) p value Male sex, [yes vs no] 5.36 (2.41-11.94) < 0.001 Black/Pardo ethnicity, [yes vs no] 0.22 (0.09-0.55) BMI, [per Kg/m²] 1.91 (1.67-2.18) Type-2 diabetes, [yes vs no] 5.79 (2.58-13.00) Dyslipidemia, [yes vs no] 2.57 (1.27-5.21) 0.01 Hypertension, [yes vs no] 2.56 (1.25-5.26) Poor clinical management, [yes vs no] 0.36 (0.17-0.79) CD4 count, [per 100 cells/mm3] 1.13 (1.01-1.27) 0.04 Cumulative HIV viral load [per 10 log *year] 1.25 (1.02-1.54) 0.03

OR (95% CI) p value HIV infection 2.1 (1.49-2.95) < 0.001 Presence of steatosis in HIV and non-HIV individuals paired by the nearest neighbor propensity score with a caliper of 0.05   OR (95% CI) p value HIV infection 2.1 (1.49-2.95) < 0.001 Logistic regression-based scores were used for matching and balance between groups was checked with usual procedures

Strenghts Limitations Multicenter study for controls (non-HIV subjects) Blood sample analysis were performed in a centralized laboratory Matching methodology (PSM) lead to very similar cases and controls based on a genetic algorithm Limitations Lack of liver biopsy or imaging methods as a gold-standard for liver steatosis and fibrosis assessment

Conclusions Traditional and HIV-specific risk factors were independently associated with liver steatosis in people living with HIV HIV-infected individuals had 2-fold higher odds for presence of steatosis compared to uninfected paired controls

Thank you for your attention Acknowledgement Participants: ELSA-Brasil study and the HIV-ELSA cohort Co-authors and colleagues: FIOCRUZ [INI-LAPCLIN-AIDS / PROCC / ENSP] University of São Paulo / University of Espirito Santo Funding support Thank you for your attention hugo.perazzo@ini.fiocruz.br